Savara (NASDAQ:SVRA) Given “Market Outperform” Rating at JMP Securities

Savara (NASDAQ:SVRA)‘s stock had its “market outperform” rating reaffirmed by analysts at JMP Securities in a note issued to investors on Thursday,Benzinga reports. They currently have a $9.00 target price on the stock. JMP Securities’ target price suggests a potential upside of 182.13% from the company’s previous close.

Several other equities analysts have also recently commented on the company. HC Wainwright cut their price target on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Evercore ISI restated an “in-line” rating and issued a $5.00 target price (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Savara presently has a consensus rating of “Moderate Buy” and an average target price of $10.17.

Savara Stock Performance

SVRA stock traded up $0.17 on Thursday, reaching $3.19. 138,171 shares of the company were exchanged, compared to its average volume of 1,266,494. The firm has a market capitalization of $547.46 million, a PE ratio of -7.42 and a beta of 0.92. Savara has a 12 month low of $2.82 and a 12 month high of $5.70. The stock’s fifty day moving average price is $3.49 and its 200 day moving average price is $4.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). On average, research analysts anticipate that Savara will post -0.45 EPS for the current fiscal year.

Insider Activity

In related news, Director Joseph S. Mccracken acquired 20,000 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was bought at an average cost of $2.95 per share, with a total value of $59,000.00. Following the completion of the acquisition, the director now owns 210,837 shares in the company, valued at $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. The trade was a 3.44 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.13% of the company’s stock.

Hedge Funds Weigh In On Savara

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SVRA. Bank of New York Mellon Corp increased its holdings in shares of Savara by 12.5% during the second quarter. Bank of New York Mellon Corp now owns 288,325 shares of the company’s stock worth $1,162,000 after buying an additional 32,142 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Savara by 967.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,008 shares of the company’s stock valued at $177,000 after purchasing an additional 39,886 shares in the last quarter. Principal Financial Group Inc. raised its position in Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after purchasing an additional 6,973 shares during the last quarter. Victory Capital Management Inc. bought a new position in Savara in the 2nd quarter valued at $527,000. Finally, Choreo LLC acquired a new position in Savara in the second quarter worth $59,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.